Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Study Phase filter
    Country filter
      News Type filter
        Company filter
          Product Type filter
            refresh

            Product Type Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Conjugated Estrogens

            Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Cenestin

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Avion Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership November 12, 2020

            Details:

            Avion Pharmaceuticals gets exclusive rights to relaunch Cenestin® in the USA. Cenestin® is the only plant-derived mixture of nine conjugated estrogens indicated for treatment of moderate to severe symptoms of vasomotor, and vulvar and vaginal atrophy due to menopause.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Norelgestromin,Ethinyl Estradiol

            Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Evra

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Gedeon Richter Plc.

            Deal Size: $263.5 million Upfront Cash: Undisclosed

            Deal Type: Acquisition December 03, 2020

            Details:

            Evra is a transdermal contraceptive patch assets. The deal is complemented by a transitional business license agreement and series of other related agreements to run the business without interruption during the period required to transfer marketing authorizations to Richter.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tranexamic Acid

            Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Lysteda

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Amring Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition December 02, 2020

            Details:

            Acquisition of the global rights to LYSTEDA® (tranexamic acid), a first-in-class, non-hormonal therapy indicated specifically for treatment of women with cyclic heavy menstrual bleeding (HMB), will further strengthen Amring's position in the marketplace.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Segesterone Acetate,Ethinyl Estradiol

            Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Annovera

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Population Council

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement November 30, 2020

            Details:

            As part of the agreement, Duchesnay will explore opportunities to register ANNOVERA with local regulatory agencies in these regions and will invest in the Population Council’s research activities to develop new innovative contraceptive products.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ebopiprant

            Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: OBE022

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 16, 2020

            Details:

            In the PROLONG study, ebopiprant reduced delivery in singleton pregnancies at 48 hours after the start of dosing by 55% compared to atosiban alone. Overall, 12.5% of women receiving ebopiprant delivered within 48 hours of starting treatment compared to placebo.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): APL-1702

            Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Cevira

            Highest Development Status: Phase III Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 11, 2020

            Details:

            APL-1702 (Cevira ® ) is a photodynamic drug device combination product. Based on the principle of photodynamics, it combines a photosensitizer with a specific wavelength of light activation to produce a therapeutic effect.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Estradiol

            Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Imvexxy

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Cantor Fitzgerald

            Deal Size: $30.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering November 10, 2020

            Details:

            TherapeuticsMD intends to use the net proceeds from the offering for commercialization of its three FDA-approved products which includes IMVEXXY®, BIJUVA® and ANNOVERA®, and for working capital and general corporate purposes.